Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis

HPB

Volumn 15, Issue 8, 2013, Pages 574-580

  Araujo, Raphael L C ^a   Gaujoux, Sébastien ^a   Huguet, Florence ^a   Gonen, Mithat ^a   D'Angelica, Michael I ^a   Dematteo, Ronald P ^a   Fong, Yuman ^a   Kingham, T Peter ^a   Jarnagin, William R ^a   Goodman, Karyn A ^a   Allen, Peter J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER SURGERY; CHEMORADIOTHERAPY; COMORBIDITY; CONFERENCE PAPER; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREAS RESECTION; PANCREATIC LEAK; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; SURGICAL MORTALITY;

EID: 84880152132     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12033     Document Type: Conference Paper

References (30)

1. Siegel R, Naishadham D, Jemal A,. (2012) Cancer statistics. CA Cancer J Clin 62: 10-29.
2. Warshaw AL, Fernández-del Castillo C,. (1992) Pancreatic carcinoma. N Engl J Med 326: 455-465. Review.
3. Tse RV, Dawson LA, Wei A, Moore M,. (2008) Neoadjuvant treatment for pancreatic cancer-a review. Crit Rev Oncol Hematol 65: 263-274. Review.
4. Joensuu TK, Kiviluoto T, Kärkkäinen P, Vento P, Kivisaari L, Tenhunen M, et al. (2004) Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60: 444-452.
5. Talamonti MS, Small W Jr, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, et al. (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13: 150-158.
6. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3496-3502.
7. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al. (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3487-3495.
8. Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. (2009) Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 250: 88-95.
9. Pipas JM, Barth RJ Jr, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, et al. (2005) Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12: 995-1004.
10. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ,. (2011) Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150: 466-473.
11. Bickenbach KA, Gonen M, Tang LH, O'Reilly E, Goodman K, Brennan MF, et al. (2012) Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol 19: 1663-1669.
12. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13: 1035-1046.
13. Grobmyer SR, Pieracci FM, Allen PJ, Brennan MF, Jaques DP,. (2007) Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg 204: 356-364.
14. Vin Y, Sima C, Getrajdman GI, Brown KT, Covey A, Brennan MF, et al. (2008) Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg 207: 490-498.
15. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. (2005) International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138: 8-13. Review.
16. Rose S, van der Laan MJ,. (2009) Why match? Investigating matched case-control study designs with causal effect estimation. Int J Biostat 5: Article1.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
18. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J,. (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7: e1000267. Review.
19. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, et al. (2012) Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 19: 1644-1662.
20. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, et al. (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208-2212.
21. Pipas JM, Mitchell SE, Barth RJ Jr, Vera-Gimon R, Rathmann J, Meyer LP, et al. (2001) Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50: 1317-1322.
22. Yavuz AA, Aydin F, Yavuz MN, Ilis E, Ozdemir F,. (2001) Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 51: 974-981.
23. Martenson JA, Vigliotti AP, Pitot HC, Geeraerts LH, Sargent DJ, Haddock MG, et al. (2003) A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 55: 1305-1310.
24. Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, et al. (2005) Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28: 345-350.
25. Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, et al. (2006) Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 95: 260-265.
26. Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, et al. (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19: 86-91.
27. Parikh P, Shiloach M, Cohen ME, Bilimoria KY, Ko CY, Hall BL, et al. (2010) Pancreatectomy risk calculator: an ACS-NSQIP resource. HPB 12: 488-497.
28. Hill JS, Zhou Z, Simons JP, Ng SC, McDade TP, Whalen GF, et al. (2010) A simple risk score to predict in-hospital mortality after pancreatic resection for cancer. Ann Surg Oncol 17: 1802-1807.
29. Kelly KJ, Greenblatt DY, Wan Y, Rettammel RJ, Winslow E, Cho CS, et al. (2011) Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality. J Gastrointest Surg 15: 250-259, discussion 259-61.
30. Zhou Y, Zhang Z, Liu Y, Li B, Xu D,. (2012) Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 36: 884-891.